Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
931 DKK | -4.02% |
|
+0.41% | +38.95% |
08:13am | Roche reports positive early results in obesity drug trial | RE |
06:31am | Dutch Health Care Wary of Reimbursing Novo Nordisk's Obesity Drug Cost | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.95% | 63TCr | |
+61.53% | 85TCr | |
-3.66% | 36TCr | |
+15.06% | 32TCr | |
+9.18% | 30TCr | |
+5.89% | 23TCr | |
+16.53% | 23TCr | |
+15.67% | 18TCr | |
+2.47% | 17TCr | |
+2.36% | 13TCr |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- NOVO NORDISK : Buy rating from JP Morgan